Strategic Market Access Solutions
Evidence Led
Commercially Focused

Delivering the complete market access strategy from development to launch success

Contact

WHAT WE DO

EU Joint Clinical Assessment

Wright Pharma Partnering Ltd designs market access strategy that is clear, evidence-based and commercially focused. We support pharmaceutical clients with structured services across global market access strategy, evidence generation, pricing narratives, value communication, and local implementation.

Working as your team member, we bring clarity and focus to every step. The goal: to deliver strategies that stand up to payer scrutiny.
Twenty years across global, regional and national HTA, brought directly to your team.

✓ Two decades of experience across the pharma industry

✓ Four years delivering client-focused results

✓ Senior consultant providing tailor made solutions

✓ Oncology and Rare Diseases

✓ Delivering a suite of Market Access solutions through preferred partnership models

Market Access Solution Design

Strategic Market Access Planning

TESTIMONIALS

  • “Elaine Wright is one of the strongest market access experts in our business. In the nearly 10 years I have worked with Elaine she has constantly provided strong technical expertise, clear, coherent strategy, and flawless execution in support of our oncology portfolio. Her tremendous skills resulted in her being a much sought expert beyond market access, HEOR and pricing, and as a result assumed roles of increasing accountability in our global commercial business and country specific strategic leadership.”

    Brian O'Shea
    Genentech

  • “Elaine has extensive expertise in Access and Value demonstration, which is consistently shown in the high quality of her work. She is detail-focused, while maintaining a strong strategic perspective. Elaine is not only reliable but also a pleasure to collaborate with. Elaine has led several projects with us, consistently demonstrating exceptional project management skills that guarantee high-quality deliverables on time. She has deep knowledge and expertise on access, value demonstration and evidence generation topics. She quickly understands your needs and is able to transform ideas into actionable, tangible outcomes. Elaine offers invaluable insights and guidance throughout the process. In summary, working with Elaine is synonymous with success and a hallmark of quality.”

    Natalia Arrabal,
    Italfarmaco

  • “Elaine brought  out-of-the-box innovative solutions and an energy to the team. A forward momentum and focus towards our common goal. Her pro-active problem-solving and collaborative approach made her a highly valuable team member. I would highly recommend Elaine as a peer resource, and I hope to work with her again in the future.”

    Maiko Liebermann,  F. Hoffmann-La Roche

  • “Thank you so much Elaine for giving this guest lecture. You explained really well the importance and the intricacies of Market Access. It was of huge benefit to the students to learn from your rich experience.”

    Ronan Mahon
    National University of Ireland, Galway. Lecturer in Health Economics

01. EU Joint Clinical Assessment

Wright Pharma Partnering supports developers across both EU HTA pathways

Shaping the evidence base early through Joint Scientific Consultation, and
Leading clients through Joint Clinical Assessment, with experience delivering a live JCA submission in oncology, currently under assessment.
Where a programme needs additional capacity in biostatistics, systematic review or medical writing, Wright Pharma Partnering leads the preferred partner team to deliver the complete package for clients.

Joint Scientific Consultation

  • Augmentation of Clinical development plan (e.g. pivotal protocol) for HTA success comparators, endpoints and surrogate endpoint validation, populations and subgroup

  • JSC Briefing package generation and PICOs simulation including competitor prediction, population structuring and Strategic HTD positioning.

  • Translation of JSC feedback into evidence planning

Joint Clinical Assessment

  • Readiness evidence gap assessment, PICO anticipation, resourcing and governance

  • Scope response scope interpretation, PICOs prioritisation, feasibility and justifications

  • Evidence systematic literature review, indirect treatment comparison, statistical oversight

  • JCA Dossier clinical narrative aligned to the commercial and medical product strategy

  • After submission managing assessor questions and responses, redaction recommendations

02. Market Access Solution Design

Market Access problem solving requires decades of experience, innovative mindset and cross functional alignment.

Leveraging out-of-the-box design thinking methodologies, AI-enabled tools and years of experience, WRIGHT Pharma Partnering supports its clients through the market access topics which, if unaddressed, have the potential to derail the entire product launch.

WRIGHT Pharma Partnering diagnose the underlying issue, understand the real question to be answered, design the solution and facilitate the resolution.

  • Most Favored Nation Risk Mitigation planning

  • PICO simulation and JCA readiness‍ ‍

  • Repeatable planning frameworks — evidence generation and tactical planning processes your country teams can run themselves

  • Integrated Evidence generation planning‍ ‍

  • Scenario planning under uncertainty‍ e.g. prior to clinical trial data readout ‍

  • Value story and payer narrative‍ building and testing ‍

03. Strategy

Global Market Access Strategy That’s Integrated

We support Market Access leaders in designing cohesive, forward-looking strategy across evidence, pricing and communication. Whether you’re developing a launch plan, testing strategic scenarios or aligning cross-functional teams, we bring clarity and structure to complex environments.

✓Market Access Strategy Development

✓Pricing Risk Scanning and Sentiment Monitoring

✓Framing the Societal Impact and Publications

✓Global Value Dossier and Value Proposition Development

✓Pricing and Access Narrative Development

✓Global to Local Message Matrix and Q&A Resource Creation, Dissemination and Training

CASE STUDIES

  • Most Favoured Nation is already impacting all areas of pharma launches in US and non-US markets. WRIGHT Pharma Partnering, along with Bambooster, have advised our client, a global pharmaceutical company on their mitigation strategy, facilitating their design thinking workshops and delivering a white paper mitigation strategy. Sizing exposure against the current policy landscape, and designing and facilitating a cross-functional workshop programme spanning global access, pricing, policy, medical, and commercial as well as country teams, to produce agreed positions for the ICP.

  • WRIGHT Pharma Partnering, as the strategy lead on a Joint Clinical Assessment, provided the strategic direction, PICOs prioritisation, evidence narrative, as well as writing the complete JCA dossier for an oncology asset. The JCA was completed in unprecedented timelines for an oncology asset. WRIGHT Pharma delivered the entire dossier along with freelance statistician Chris Poole and evidence synthesis Waseem Ahmed.

    The JCA is currently under review and WPP have guided the client through the first round of questions.

  • Wright Pharma Partnering was engaged as the specialist market access partner to a consultancy leading a client engagement for a cell and gene therapy product, delivering the fully drafted JSC briefing book on time and to the standard required for HTA Coordination Group review. A defensible strategic submission that positions the client's pivotal Phase III trial for a successful future Joint Clinical Assessment.

    The engagement covered the full scope of what a competitive JSC submission requires: strategic PICO architecture grounded in European clinical treatment guidelines; competitor intelligence across published HTA and JCA precedent in the therapy area; augmentation of the client's pivotal clinical trial protocol; anchored MAIC methodology and feasibility assessment for the indirect treatment comparison; evidence gap analysis with structured mitigation strategy design; and end-to-end drafting of all Section 1, 2, 3 and 4 content aligned to the JSC template. Delivered through a partnership model that combined our senior market access expertise with the client consultancy's programme leadership, this engagement demonstrates how Wright Pharma Partnering supports clinical-stage biotechs and their consulting partners preparing high-stakes JSC and JCA submissions across European markets. Turning a regulatory milestone into a strategic evidence-generation reference point that shapes the pivotal trial's future JCA.

  • Based on our research, client needs and hand-on experience with AI, WRIGHT Pharma Partnering, in collaboration with MARS, have constructed a five domain framework to assess and boost our clients’ AI readiness in market access.

    LINK: Published at ISPOR 2025‍ ‍

    • Strategic Leadership

    • Data Excellence & Technology

    • People, Skills & Culture‍

    • Governance & Ethics

    • Continuous Improvement & Adaptation

  • Supported a mid-size biopharma with a sensitive EU launch by developing a unified pricing and access narrative. Through structured interviews and workshops, we translated complex data into clear messaging, ensuring consistency across the organisation and strengthening internal communication.

  • Created accessible, visual training modules to improve understanding of network meta-analysis among medical and commercial teams. Helped the client build internal capability to confidently communicate HTA-published evidence and engage more effectively with payers.

    LINK: Sample NMA Training (visual only) for Non-HEOR colleagues

  • Guest lecture introducing Global Market Access Strategy to students at NUI Galway MSc in Health Economics.

  • Market Access AI Readiness Framework

    Duchenne Muscular Dystrophy HEOR Model

    Treatment Switching Statistical Publication

    Trials and Tribulations of Treatment Switching Practical Experience with Statistical Methods

    Other publications

A smiling young woman with shoulder-length brown hair, earrings, a white top, and a gold pendant necklace, sitting indoors with a colorful floral painting and green wall in the background.

WRIGHT Pharma Partnering Ltd delivers clear, evidence-based market access strategy for pharmaceutical companies.

Founded in 2022 by Elaine Wright, the company offers direct access to senior expertise without the overhead of a large consultancy. Clients work one-to-one with the principal consultant for strategic depth, continuity and practical support.

The focus: high-stakes access challenges, modular tools for planning, and readiness for AI-enabled decision-making always delivered with clarity, structure and outcomes in mind.

Brian O'Shea, Genentech

“Elaine Wright is one of the strongest market access experts in our business…”

Natalia Arrabal, Italfarmaco 

​“…working with Elaine is synonymous with success and a hallmark of quality.”